Inogen Stock News

Inogen came in with a mixed set of numbers, however, longer-term structural headwinds remain in situ. The hold rating on INGN remains intact following Q2 earnings, and I've noticed similar themed risk

Inogen's (INGN) second-quarter results benefit from higher revenues in its international business-to-business sales channel.

Inogen, Inc. (NASDAQ:INGN ) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET Company Participants Agnes Lee - SVP of IR and Strategic Planning Nabil Shabshab - President and CEO Kristin Calt

Inogen (INGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t

Inogen (INGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced that it will release seco

Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.

Stifel has decided to maintain its Hold rating of Inogen (NASDAQ:INGN) and lower its price target from $40.00 to $30.00. Shares of Inogen are trading down 4.15% over the last 24 hours, at $23.91 per s

Inogen, Inc. (NASDAQ:INGN ) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Jason Somer - General Counsel Nabil Shabshab - President & CEO Kristin Caltrider - CFO Conferen

Inogen (INGN) delivered earnings and revenue surprises of 20.83% and 5.09%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Inogen (INGN) delivered earnings and revenue surprises of 20.83% and 5.09%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced that it will release firs

Supply chain issues have hit Inogen hard, undermining the company's ability to ship to demand and driving some share loss despite healthy underlying demand trends.

Inogen (INGN) continues to benefit from strength in the direct-to-customer business model. However, rising costs remain a woe.

Inogen (INGN) continues to benefit from strength in the direct-to-customer business model. However, rising costs remain a woe.